New Tracer Reveals How Tumors Fuel Growth with Fat | King’s College London

A newly developed imaging tracer is offering researchers a clearer picture of how tumors utilize fat as a primary fuel source, a finding that could reshape our understanding of cancer metabolism and potentially lead to more targeted therapies. The study, conducted at King’s College London, introduces a non-invasive method for visualizing and quantifying fat consumption within cancerous tissues.

Understanding the Metabolic Shift in Cancer

Our bodies rely on a variety of nutrients – carbohydrates, proteins, and fats – to provide the energy needed for all bodily functions. However, when disease develops, such as in cancer or heart disease, the way tissues utilize these nutrients can change dramatically. Tumors, in particular, often exhibit distinct metabolic characteristics compared to normal tissues, frequently showing an increased dependence on specific nutrients to support their rapid growth and survival. This new research focuses on that dependence on fat.

The King’s College London study, detailed in a recent report, highlights the importance of understanding these metabolic dependencies. By pinpointing and analyzing how tumors utilize fats, scientists hope to develop therapeutic strategies that specifically target these vulnerabilities within malignant cells. The imaging tracer allows researchers to track the uptake and utilization of fatty acids within cancerous tissues, providing valuable insights into the metabolic dynamics driving tumor growth. More details on tumor metabolism can be found here.

Beyond Breast Cancer and Melanoma: A Broader Implication

While the initial research focused on tumor tissue from 99 patients with melanoma skin cancer and breast cancer, the implications extend far beyond these two cancer types. Researchers at King’s College London, building on almost a decade of operate that began at King’s, compared their findings to cancers from patients with 14 different tumor types, including lung cancer, pancreatic cancer, and glioblastoma – an aggressive form of brain cancer. The study published in Nature Communications found that a higher presence of certain genes associated with this metabolic shift was associated with shorter survival times across these various cancers.

This suggests that the way cancer cells alter their surroundings to access and utilize fats may be a common mechanism across a wide range of aggressive tumors. The extracellular matrix (ECM), the structure surrounding tumors, plays a crucial role in this process. The research team discovered that cancer cells use the layout of the ECM as a “roadmap” to leave the tumor, triggering changes in their shape and boosting their ability to travel to other parts of the body.

The Role of the Extracellular Matrix

Tumors aren’t simply masses of cells; they are complex ecosystems held together by the ECM, often described as the scaffolding around a building under construction. This structure isn’t static; cancer cells actively interact with and remodel the ECM to facilitate their spread. The recent findings indicate that the ECM’s layout directly influences how cancer cells change shape and grow more mobile, effectively enabling metastasis – the process by which cancer spreads to other parts of the body.

Identifying aggressive tumors likely to metastasize at an earlier stage is a critical step in improving patient outcomes. The ability to pinpoint these tumors sooner allows clinicians to tailor treatment plans more effectively. Currently, drugs are in development to target both the ECM’s layout and the genes that drive these cell shape changes, offering the potential to stop cancer in its tracks before it can escape the primary tumor.

What Does This Mean for Patients?

It’s important to emphasize that this research is still in its early stages. The imaging tracer is a valuable tool for understanding tumor metabolism, but it is not yet a diagnostic test available to patients. The findings do, however, offer a promising avenue for future research and the development of new therapies.

The study doesn’t suggest any immediate changes to current cancer treatment protocols. Patients should continue to follow the guidance of their healthcare providers and adhere to established treatment plans. Cancer Research UK provides comprehensive information about cancer types, treatments, and ongoing research.

Limitations and Future Directions

The initial study involved a relatively small sample size (99 patients), which limits the generalizability of the findings. Further research with larger and more diverse patient populations is needed to confirm these results and explore the potential for clinical application. The study focused primarily on melanoma and breast cancer; more research is needed to determine whether the same mechanisms are at play in other cancer types.

Researchers are too investigating the development of drugs that specifically target the ECM and the genes involved in cell shape changes. These drugs are currently in preclinical development, and it will take time to determine their safety and efficacy in humans.

The Ongoing Process of Cancer Research

The development of new cancer therapies is a complex and iterative process. Research findings like these contribute to a growing body of knowledge that informs the development of new diagnostic tools and treatment strategies. The process typically involves several stages, including laboratory research, preclinical studies (in animals), clinical trials (in humans), and regulatory approval.

Ongoing surveillance and data collection are crucial for monitoring cancer trends and evaluating the effectiveness of new interventions. Public health agencies, such as the Centers for Disease Control and Prevention (CDC), play a vital role in this process. They collect data on cancer incidence, mortality, and risk factors, and use this information to develop and implement cancer prevention and control programs.

What’s next: Researchers will continue to refine the imaging tracer and explore its potential for use in clinical trials. They will also investigate the underlying mechanisms that drive the metabolic shift in cancer cells, with the goal of identifying new therapeutic targets. Further studies are planned to assess the effectiveness of drugs targeting the ECM and cell shape changes in preclinical models and, eventually, in human patients.